Biotech News

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Roivant (ROIV)Roivant2026-04-02 09:00 ESTClinical readout

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies exist for LPP, highlighting a critical unmet therapeutic need LPP marks the

Roivant

Vant Operating Model Roivant develops and commercializes medicines through focused subsidiaries known as Vants. The structure gives individual programs dedicated teams while retaining access to the parent company's capital, development and commercialization capabilities. Brepocitinib Autoimmune Franchise Brepocitinib is an oral JAK1/TYK2...

Recent company news

ROIVRoivant2026-08-06 11:00 EST

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

ROIVRoivant2026-08-06 11:00 EST

Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

ROIVRoivant2026-07-23 20:05 EST

Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

ROIVRoivant2026-05-20 11:00 EST

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

ROIVRoivant2026-05-11 20:05 EST

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

Stock data

Close: 36.30 USD
Market cap: 20.32B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States